



The RICH network

The RICH Hepatocellular Carcinoma Trials Network is recently founded, nationwide group of investigators that has grown out of the CARNOR network in north-western France.

Key facts about HCC

Hepatocellular carcinoma (HCC) is the most frequent malignant primary liver cancer. It results from the neoplastic proliferation of hepatocytes.

Most cases of HCC are linked to a underlying, chronic liver disease of some kind. This is why HCC patients tend to be monitored and cared for by hepatogastroenterologists rather than oncologists.

The rising incidence of this tumour and the recent emergence of novel, potential treatments have made HCC an increasingly active research theme.

This context has prompted the creation of the RICH network as France's only clearing house for industry-sponsored clinical trials in the field of HCC.



rich@chu-amiens.fr

Coordinator:
Jean-Claude Barbare MD

CHU Amiens Nord
1, Place Victor Pauchet
F-80054 Amiens cedex 1; France
☎ : +33 322 668060
Mobile : +33 679 63080


✉ : barbare.jeanclaude@chu-amiens.fr

Project Manager:
Amandine Bellenguez


CHU Amiens Nord
1, Place Victor Pauchet
F-80054 Amiens cedex 1; France
☎ : +33 322 667733
Mobile : +33 678 455871

✉ : bellenguez.amandine@chu-amiens.fr

✉ : rich@chu-amiens.fr



"For efficient, rapid and high-quality recruitment"



The RICH network's resources

- @ 43 centres throughout France: 27 university hospitals, 7 cancer centres, 4 regional and local hospitals, 1 cancer institute, 1 clinical investigation centre and 3 private clinics
- @ 6 learned societies have approved participation in the network
- @ 1 steering committee, constituted by representatives of 7 regional clinical research directorates and the learned societies.
- @ 100 investigators
- @ 30 clinical research associates and technicians

RICH's commitments

- ❖ To measure, structure and optimize the procedures and organizational structures for pre-screening
- ❖ To facilitate and improve patient inclusion, in compliance with GCP and regulatory procedures
- ❖ To estimate trial feasibility and the inclusion potential at various centres
- ❖ To monitor inclusions in real time
- ❖ To create a national register of industry-sponsored trials on HCC
- ❖ To develop and harmonize procedures and tools for administrative and financial management as part of a quality-focused approach

RICH



The RICH network's unique advantages

Internet-based tools for the management of multicentre, industry-sponsored clinical trials on HCC, including 3 different modules:

Professional information

Directory of contacts / event diary / newsletter / calls for tenders / protocols / common procedures / medical documentation

BASARS software*

For monitoring industry-sponsored clinical trials on HCC (including real-time information on inclusions)

SPOT software**

Enables the management of standardized, multidisciplinary staff meetings in several centres, for better visualization of the inclusion potential and for immediate identification of eligible patients in industry-sponsored clinical trials on HCC

